- Home
- MBRX vs QNRX Comparison
MBRX vs QNRX Comparison
Compare MBRX & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBRX | QNRX |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 11.6M |
| IPO Year | 2016 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MBRX | QNRX |
|---|---|---|
| Price | $2.38 | $4.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $61.00 | N/A |
| AVG Volume (30 Days) | ★ 258.5K | 29.0K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $4.11 |
| 52 Week High | $7.98 | $41.80 |
Technical Indicators
Market Signals| Indicator | MBRX | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 34.47 |
| Support Level | $2.16 | N/A |
| Resistance Level | $2.64 | $6.84 |
| Average True Range (ATR) | 0.20 | 0.44 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 19.40 | 34.71 |
Price Performance
Historical ComparisonAbout MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.